Chemicals and pharmaceuticals · AGRX

AGILE THERAPEUTICS INC

12 filings mentioning 7 of the compliance and risk topics we track. Every row links to the filing on EDGAR.

12filings we hold
7topics disclosed
Chemicals and pharmaceuticalsindustry
NJbased in

Across 12 filings we hold, AGILE THERAPEUTICS INC has written down 7 of the topics we track. That places it 338 of 737 companies we hold in chemicals and pharmaceuticals, by how much we have collected.

AGRX Chemicals and pharmaceuticals

What this obligates

Every instrument in our corpus that governs something AGILE THERAPEUTICS INC has written into a filing. Not what they said. What applies once they have said it.

NIST Cybersecurity Framework 2.078
ISO 27001:202242
ISO 37001:201639
ASD Strategies to Mitigate Cyber Security Incidents29
ISO 3700126
COSO Internal Control9
Basel III International Banking Framework6
NIST SP 800-615
PCAOB AS 22014
IFRS 172

10 frameworks, 240 controls between them, deduplicated across topics.

What it discloses

Tracked topics appearing in this company's filings, most frequent first.

Internal Control9
Consent Order8
Ransomware3
Enforcement Action2
Material Weakness2
Restatement2
Regulatory Reporting1

Bars are scaled against this company's most frequent topic, not against the market. The table below has the exact counts.

TopicFilingsMost recent
Internal Control92024-06-26
Consent Order82022-04-27
Ransomware32024-03-28
Enforcement Action22020-02-12
Material Weakness22023-02-27
Restatement22023-02-27
Regulatory Reporting12021-03-01

When it filed

Filings we hold, by year. Hover a bar for the count.

19
20
21
22
23
24

Recent filings

FiledFormItem
2024-06-268-KEntry into a material agreement, Regulation FD disclosure, Financial statements and exhibitsfiling
2024-03-2810-Kfiling
2023-05-258-KEntry into a material agreement, Item 3.03, Other material eventfiling
2023-03-2310-Kfiling
2023-02-278-KFinancial statements no longer reliable, Other material event, Financial statements and exhibitsfiling
2023-01-268-KItem 3.03, Item 5.03, Regulation FD disclosurefiling
2022-07-088-KEntry into a material agreement, Other material event, Financial statements and exhibitsfiling
2022-04-278-KEntry into a material agreement, Item 1.02, Results of operations, the earnings releasefiling
2022-03-3010-Kfiling
2022-03-158-KEntry into a material agreement, Item 3.03, Item 5.03filing
2022-01-108-KEntry into a material agreement, Results of operations, the earnings release, Item 2.03filing
2021-10-088-KDirector or officer departure, Regulation FD disclosure, Other material eventfiling

Others in chemicals and pharmaceuticals

The companies we hold most on in the same industry. Each opens side by side with this one.

CompanyFilings
OPKOPKO HEALTH, INC.12compare →
FGENFIBROGEN INC12compare →
PTNPALATIN TECHNOLOGIES INC12compare →
OTLCOncotelic Therapeutics, Inc.12compare →
NKTRNEKTAR THERAPEUTICS12compare →
APALEXION PHARMACEUTICALS, INC.12compare →
New here? Signals tracks the compliance and risk language public companies put into their SEC filings, and cross-references it against 723 frameworks and 20,473 controls. See what moved today or check how much of a framework you already cover.

What this page is

Every row comes from SEC full-text search over this company's filings, matched against the compliance and risk phrases we track. It is a record of what the company itself wrote down in documents it is legally accountable for. It is not an assessment of the company, a rating, or a claim about how well it manages anything.

A phrase appearing in a filing frequently means the risk section mentions it, not that an event occurred. Where an item number indicates an actual event, the Item column says so.

All of chemicals and pharmaceuticals · All companies · Today's edition